ArticleCellular & molecular immunology2012
CDR3δ -grafted γ9δ2T cells mediate effective antitumor reactivity.
Article in Cellular & molecular immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- BTN3A1 regulate the function of Vγ9Vδ2 T cells through TCR signaling pathway in ovarian cancer.Journal of ovarian research · 2026Article
- γδ T-cell autoresponses to ectopic membrane proteins: a new type of pattern recognition.Cellular & molecular immunology · 2025Article
- Progress of research on γδ T cells in colorectal cancer (Review).Oncology reports · 2024Review
- Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach.Vaccines · 2022Review
- Engineering γδ T Cells: Recognizing and Activating on Their Own Way.Frontiers in immunology · 2022Review
- γδ T Cells in Peripheral Blood of Glioma Patients.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- The Generation of Human γδT Cell-Derived Induced Pluripotent Stem Cells from Whole Peripheral Blood Mononuclear Cell Culture.Stem cells translational medicine · 2018Article
- Current Advances in γδ T Cell-Based Tumor Immunotherapy.Frontiers in immunology · 2017Review
- TCRγ4δ1-engineered αβT cells exhibit effective antitumor activity.Molecular medicine (Cambridge, Mass.) · 2016Article
- Chaperonin-containing T-complex Protein 1 Subunit ζ Serves as an Autoantigen Recognized by Human Vδ2 γδ T Cells in Autoimmune Diseases.The Journal of biological chemistry · 2016Article
- Analysis of tumor-infiltrating gamma delta T cells in rectal cancer.World journal of gastroenterology · 2016Article
- The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy.Cellular & molecular immunology · 2015Review
- Hyperactivation and in situ recruitment of inflammatory Vδ2 T cells contributes to disease pathogenesis in systemic lupus erythematosus.Scientific reports · 2015Article
- T-cell-associated cellular immunotherapy for lung cancer.Journal of cancer research and clinical oncology · 2015Review
- Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Oncoimmunology · 2013Article
- Vγ9Vδ2-T lymphocytes have impaired antiviral function in small-for-gestational-age and preterm neonates.Cellular & molecular immunology · 2013Article
- Human Vγ9Vδ2-T cells efficiently kill influenza virus-infected lung alveolar epithelial cells.Cellular & molecular immunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adoptive cell-transfer therapy (ACT) has been reported to suppress growing tumors and to overcome tumor escape in animal models. As a candidate ACT effector, γ9δ2T cells can be activated and expanded in vitro and in vivo and display strong antitumor activity against colorectal, lung, prostate, ovarian and renal cell carcinomas. However, it is difficult to obtain a large enough number of γδT cells to meet the need for immunotherapy that can overcome the cancer patients' immune suppressive tumor microenvironment. In previous studies, our lab confirmed that γ9δ2T cells recognized tumor cells via the CDR3δ region of the γδ-T-cell receptor (TCR). We constructed full-length human peripheral blood mononuclear cell (PBMC)-derived γ9 and δ2 chains in which the CDR3 region was replaced by an ovarian epithelial carcinoma (OEC)-derived CDR3. We transferred the CDR3δ-grafted γ9δ2TCR into peripheral blood lymphocytes (PBLs) to develop genetically modified γ9δ2T cells. In vitro studies have shown that these CDR3δ-grafted γ9δ2T cells can produce cytokines after stimulation with tumor cell extracts and exhibit cytotoxicity towards tumor cells, including human OEC and cervical adenocarcinoma. CDR3δ-grafted γ9δ2T cells adoptively transferred into nude mice bearing a human OEC cell line demonstrated significant antitumor effects. These results indicate that CDR3δ-grafted γ9δ2T cells might be candidates for clinical tumor immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.